A case of HCC successfully treated with infliximab-steroid sequential therapy for small bowel perforation due to atezolizumab/bevacizumab combination therapy.

Satoru HagiwaraYoriaki KomedaNaoshi NishidaAkihiro YoshidaMasatoshi Kudo

Published in: Cancer reports (Hoboken, N.J.) (2022)

There are no reports of gastrointestinal perforation by atezolizumab/bevacizumab for hepatocellular carcinoma, and prior administration of infliximab. We therefore report the clinical course and management.

Keyphrases

combination therapy
small bowel
metastatic colorectal cancer
ulcerative colitis
adverse drug
emergency department
drug induced